Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? Reply

被引：0
|
作者：
Trauner, Michael [1 ]
Chung, Chuhan [2 ]
Myers, Robert P. [2 ]
Kowdley, Kris V. [3 ]
机构：
[1] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Med 3, Vienna, Austria
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[3] Liver Inst Northwest, Seattle, WA USA
来源：
HEPATOLOGY | 2020年 / 72卷 / 04期
关键词：
D O I：
10.1002/hep.31268
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1498 / 1499
页数：2
相关论文
共 14 条
  • [1] Letter to the Editor: Could Butyrate Be Incorporated With FarnesoidXReceptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Chen, Jiezhong
    Vitetta, Luis
    HEPATOLOGY, 2020, 72 (04) : 1497 - 1498
  • [2] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
    Trauner, Michael
    Gulamhusein, Aliya
    Hameed, Bilal
    Caldwell, Stephen
    Shiffman, Mitchell L.
    Landis, Charles
    Eksteen, Bertus
    Agarwal, Kosh
    Muir, Andrew
    Rushbrook, Simon
    Lu, Xiaomin
    Xu, Jun
    Chuang, Jen-Chieh
    Billin, Andrew N.
    Li, Georgia
    Chung, Chuhan
    Subramanian, G. Mani
    Myers, Robert P.
    Bowlus, Christopher L.
    Kowdley, Kris V.
    HEPATOLOGY, 2019, 70 (03) : 788 - 801
  • [3] Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)
    Levy, Cynthia
    Caldwell, Stephen
    Mantry, Parvez
    Luketic, Velimir
    Landis, Charles
    Huang, Jonathan
    Mena, Edward
    Maheshwari, Rahul
    Rank, Kevin
    Xu, Jun
    Lu, Xiangyu
    Lu, Xiaomin
    Chung, Chuhan
    Myers, Robert
    Kowdley, Kris
    JOURNAL OF HEPATOLOGY, 2022, 77 : S319 - S320
  • [4] PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
    Michael Trauner
    Chuhan Chung
    Kate Sterling
    Xiangyu Liu
    Xiaomin Lu
    Jun Xu
    Clare Tempany-Afdhal
    Zachary D. Goodman
    Martti Färkkilä
    Atsushi Tanaka
    Palak Trivedi
    Kris V. Kowdley
    Christopher L. Bowlus
    Cynthia Levy
    Robert P. Myers
    BMC Gastroenterology, 23
  • [5] PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
    Trauner, Michael
    Chung, Chuhan
    Sterling, Kate
    Liu, Xiangyu
    Lu, Xiaomin
    Xu, Jun
    Tempany-Afdhal, Clare
    Goodman, Zachary D.
    Faerkkilae, Martti
    Tanaka, Atsushi
    Trivedi, Palak
    Kowdley, Kris V.
    Bowlus, Christopher L.
    Levy, Cynthia
    Myers, Robert P.
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [6] Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor
    Hameed, Hassan
    Irshad, Nida
    Yousaf, Muhammad Abrar
    Mumtaz, Sidra
    Sohail, Imran
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024, 82 (02) : 767 - 776
  • [7] Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver DiseaseS
    Hollenback, David
    Hambruch, Eva
    Fink, Gero
    Birkel, Manfred
    Schulz, Andreas
    Hornberger, Martin
    Liu, Kathy
    Staiger, Kelly MacLennan
    Krol, Helen Desiree
    Deuschle, Ulrich
    Steeneck, Christoph
    Kinzel, Olaf
    Liles, John T.
    Budas, Grant
    Watkins, William J.
    Kremoser, Claus
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2024, 389 (01): : 61 - 75
  • [8] Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis
    Akepati, Prithvi Reddy
    Gochanour, Eric M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (06) : 627 - 638
  • [9] Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment? Reply
    Arase, Yoshitaka
    Kagawa, Tatehiro
    Tanaka, Atsushi
    HEPATOLOGY, 2020, 72 (01) : 360 - 361
  • [10] THE NONSTEROIDAL FARNESOID X RECEPTOR (FXR) AGONIST CILOFEXOR IMPROVES LIVER BIOCHEMISTRY IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Kowdley, Kris V.
    Minuk, Gerald Y.
    Pagadala, Mangesh R.
    Gulamhusein, Aliya
    Swain, Mark Gordon
    Neff, Guy W.
    Zogg, Donald
    Bowlus, Christopher L.
    Agarwal, Kosh
    Yoshida, Eric M.
    Li, Yao
    Li, Georgia
    Chung, Chuhan
    Subramanian, Mani
    Myers, Robert P.
    Sheikh, Aasim M.
    Shiffman, Mitchell L.
    Fickert, Peter
    HEPATOLOGY, 2019, 70 : 31A - 32A
12